AN1 Stock Overview
Operates as a health and beauty tech company in Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Anagenics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.008 |
| 52 Week High | AU$0.026 |
| 52 Week Low | AU$0.006 |
| Beta | -1.03 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -63.64% |
| 33 Year Change | -87.30% |
| 5 Year Change | -96.00% |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| AN1 | AU Personal Products | AU Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -0.5% |
| 1Y | -63.6% | 75.6% | 16.0% |
Return vs Industry: AN1 underperformed the Australian Personal Products industry which returned 75.6% over the past year.
Return vs Market: AN1 underperformed the Australian Market which returned 16% over the past year.
Price Volatility
| AN1 volatility | |
|---|---|
| AN1 Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 13.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: AN1's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine AN1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Karen Matthews | anagenics.com |
Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis.
Anagenics Limited Fundamentals Summary
| AN1 fundamental statistics | |
|---|---|
| Market cap | AU$3.69m |
| Earnings (TTM) | -AU$7.28m |
| Revenue (TTM) | AU$10.80m |
0.3x
P/S Ratio-0.5x
P/E RatioIs AN1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AN1 income statement (TTM) | |
|---|---|
| Revenue | AU$10.80m |
| Cost of Revenue | AU$6.44m |
| Gross Profit | AU$4.36m |
| Other Expenses | AU$11.65m |
| Earnings | -AU$7.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 40.37% |
| Net Profit Margin | -67.43% |
| Debt/Equity Ratio | 10.0% |
How did AN1 perform over the long term?
See historical performance and comparison